Related Experiment Video
Updated: Jul 30, 2025
09:37
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
15.1K
Beta-adrenergic blockade in cirrhosis - harmful or helpful?
Søren Møller1,2, Karen V Danielsen3, Puria Nabilou3
1Dept. Clinical Physiology and Nuclear Medicine, Center for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, Hvidovre, Denmark.
Expert Review of Gastroenterology & Hepatology
|May 19, 2023
Summary
Beta-blockers are used to prevent esophageal bleeding in cirrhosis patients with portal hypertension. However, caution is advised due to potential adverse reactions in advanced cirrhosis, especially with decompensated ascites or renal dysfunction.
Area of Science:
- Hepatology and Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Portal hypertension significantly worsens cirrhosis progression, leading to severe complications like variceal bleeding, ascites, and encephalopathy.
- Beta-blockers have been a long-standing treatment for preventing esophageal variceal bleeding.
- Emerging evidence indicates potential adverse effects of beta-blockers in patients with advanced cirrhosis.
Approach:
- This review synthesizes current evidence on portal hypertension pathophysiology.
- It examines the pharmacological actions of beta-blockers in this context.
- The review also assesses their efficacy in preventing variceal bleeding and impact on decompensated cirrhosis, ascites, and renal dysfunction.
Key Points:
- Diagnosis of portal hypertension relies on direct portal pressure measurements.
- Nonselective beta-blockers and carvedilol are first-line for variceal bleeding prophylaxis.
- Treatment requires careful consideration in patients with decompensated cirrhosis, particularly those with ascites or renal dysfunction.
Conclusions:
- Beta-blockers remain crucial for managing portal hypertension complications.
- Careful patient selection and monitoring are essential, especially in advanced disease stages.
- Future management should focus on personalized treatment strategies tailored to individual disease progression.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
398
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
398
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
898
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
898
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
527
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
527
01:17Antihypertensive Drugs: Action of β1 Blockers
494
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
494
01:28Antihypertensive Drugs: Types of β-Blockers
768
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
768
01:26Adrenergic Receptors: β Subtype
1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K